Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...
The three-year OS rate was 74% in the belantamab mafodotin combination arm and 60% in the daratumumab combination arm. The ...
GSK plc (NYSE:GSK) announced statistically significant and clinically meaningful overall survival (OS) results from a planned ...
The DREAMM-7 trial shows belantamab mafodotin combined with bortezomib and dexamethasone significantly improves overall ...
2d
Wellington Management Group LLP lifted its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 47.1% during the third quarter, Holdings Channel reports. The institutional ...
As many parents know, the autumn and winter months bring a surge of coughs, colds, and fevers, often seeming like a child is ...
This study examined the role of the dorsal medial prefrontal cortex of mice in anticipating reward-value switch points in a two-armed bandit task. They demonstrate the dorsal medial prefrontal cortex ...
Department of Neurobiology and Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, USA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback